会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PYRIMIDOTHIOPHENE COMPOUNDS
    • 吡咯烷酮化合物
    • US20090069336A1
    • 2009-03-12
    • US11632969
    • 2005-07-18
    • Xavier Barril-AlonsoPaul Andrew BroughMartin James DrysdalePaul Webb
    • Xavier Barril-AlonsoPaul Andrew BroughMartin James DrysdalePaul Webb
    • A61K31/519C07D495/04A61K31/496A61P35/00A61P31/12A61P17/00A61P3/00
    • C07D495/04
    • Compounds of formula (I) are inhibitors of HSP90, and useful in the treatment of, for example, cancers: wherein R2 is a group of formula (IA): -(Ar1)m-(Alk1)p-(Z)r-(Alk2)s-Q  (IA) wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is (i) hydrogen, a —CN group, a nitro group —NO2, or a —C(═NOH)(NH2) group, or (ii) an optionally substituted C1-C6alkyl, aryl, heterocyclic, aryl(C1-C6alkyl)-, or heterocyclic(C1-C6alkyl)- group, or (iii) a group of formula —C(═O)R5 wherein R5 is hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1-C6alkyl)-, or heteroaryl(C1-C6alkoxy)-, or (iv) a group of formula —C(═O)NHR6 wherein R6 is primary, secondary, tertiary or cyclic amino, or hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1-C6alkyl)-, or heteroaryl(C1-C6alkoxy)-.
    • 式(I)化合物是HSP90的抑制剂,可用于治疗例如癌症:其中R2是式(IA)的基团:<?在线公式描述=“在线公式”末端 =“引线”→(Ar1)m-(Alk1)p-(Z)r-(Alk2)sQ(IA)<?in-line-formula description =“In-line Formulas”end =“tail”? 其中在任何相容的组合中,Ar1是任选取代的芳基或杂芳基,Alk1和Alk2是任选取代的二价C 1 -C 3亚烷基或C 2 -C 3亚烯基,m,p,r和s独立地为0或1,Z为 - (-S) - , - (CO) - , - (CS) - , - SO 2 - -SO 2 NR - , - NRAC(-O) - , - NRASO 2 - 或-NRA-,其中RA是氢或C 1 -C 6烷基,Q是氢或任选取代的碳环或杂环基; R 3是氢,任选的取代基,或任选取代的(C 1 -C 6)烷基,芳基或杂芳基; 和(i)氢,-CN基,硝基-NO 2或-C(-NOH)(NH 2)基团,或(ii)任选取代的C 1 -C 6烷基,芳基,杂环,芳基 -C 1-6烷基) - 或杂环(C 1 -C 6烷基) - 基团,或(iii)式-C( - ) - R 5基团,其中R 5是羟基,任选取代的C 1 -C 6烷基,C 1 -C 6烷氧基,芳基,芳氧基,杂芳基 ,杂芳基(C 1 -C 6烷基) - ,芳基(C 1 -C 6烷氧基) - ,杂芳基(C 1 -C 6烷基) - 或杂芳基(C 1 -C 6烷氧基) - 或(ⅳ)式-C NHR 6,其中R 6是伯,仲,叔或环状氨基,或羟基,任选取代的C 1 -C 6烷基,C 1 -C 6烷氧基,芳基,芳氧基,杂芳基,杂芳氧基,芳基(C 1 -C 6烷基) 杂芳基(C 1 -C 6烷基) - 或杂芳基(C 1 -C 6烷氧基) - 。
    • 2. 发明申请
    • Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors
    • 用作HSP90抑制剂的吡咯并嘧啶衍生物
    • US20090163490A1
    • 2009-06-25
    • US12282526
    • 2007-03-09
    • Paul Andrew BroughMartin James DrysdaleNicholas Gareth DaviesNicolas Noel FoloppeStephen Stokes
    • Paul Andrew BroughMartin James DrysdaleNicholas Gareth DaviesNicolas Noel FoloppeStephen Stokes
    • A61K31/5377C07D487/04A61P31/12A61K31/519
    • C07D487/04
    • Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk1-(Z)m-(Alk2)n-Q wherein X is —O—, —S— —S(O)—, SO2—, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—, —SO2—, —NRA—, or, in either orientation —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, or —NRASO2— wherein RA is hydrogen or C1-C6 alkyl AIk1 and AIk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, n and p are independently 0 or 1, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is a radical of formula —(Ar1)p-(Alk1)q-(Z)r-(Alk2)s-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1, Alk2, Z, and Q are as defined above, and p, q, r and s are independently 0 or 1; and R3 is cyano (—CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, —OH, —CH2OH, —C(O)NH2, —C(O)CH3, Or —NH2.
    • 式(I)化合物具有HSP90抑制活性,因此可用于治疗尤其是癌症:式(I)其中R 1是氢,氟,氯,溴或式-X-Alk1-( Z)m-(Alk2)nQ其中X是-O - , - S-S(O) - ,SO2-或-NH-,Z是-O - , - S-, -​​ (CO) ( - ) - , - ( - O - ) - , - ( - O - ) - , - ( - - , - SO 2 -NRA - , - NRAC(-O) - 或-NRASO 2 - ,其中RA为氢或C 1 -C 6烷基,Alk 1和Alk 2为任选取代的二价C 1 -C 3亚烷基或C 2 -C 3亚烯基,m,n和p 独立地为0或1,并且Q为氢或任选取代的碳环或杂环基; R2是式 - (Ar1)p-(Alk1)q-(Z)r-(Alk2)sQ的基团,其中Ar1是任选取代的芳基或杂芳基,Alk1,Alk2,Z和Q如上定义, 和p,q,r和s独立地为0或1; 并且R 3是氰基(-CN),氟,氯,溴,其中一个或多个氢原子任选被氟原子取代的甲基,其中一个或多个氢原子任选被氟原子取代的乙基,环丙基 ,-OH,-CH 2 OH,-C(O)NH 2,-C(O)CH 3或-NH 2。
    • 4. 发明申请
    • Pyrimidothiophene Compounds Having HSP90 Inhibitory Activity
    • 具有HSP90抑制活性的嘧啶并噻吩化合物
    • US20090054421A1
    • 2009-02-26
    • US11795523
    • 2006-01-23
    • Thomas Peter MatthewsKwai Ming CheungIan CollinsEdward McDonaldPaul Andrew BroughMartin James Drysdale
    • Thomas Peter MatthewsKwai Ming CheungIan CollinsEdward McDonaldPaul Andrew BroughMartin James Drysdale
    • A61K31/5377C07D495/04A61K31/519
    • C07D495/04
    • Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R1 is -(Alk1)p-(Z)r(Alk2)-Q wherein AIk1 and AIk2 are optionally substituted divalent C1C3 alkylene or C2-C3 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —C(═O)O—, —C(═O)NRA, —C(═S)NRA-, —SO2NRA—NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is optionally substituted aryl or heteroaryl; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C-6)alkyl, aryl or heteroaryl radical; and R4 is (i) a carboxylic ester, carboxamide or sulfonamide group, or (ii) a —CN group, or (iii) an optionally substituted C1-C6alkyl, aryl, heteroaryl, aryl(C1-C6alkyl)-, or heteroaryl(C1-C6alkyl)- group, or (iv) a group of formula —C(═O)R5 wherein R5 is hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1-C6alkyl)-, or heteroaryl(C1-C-6alkoxy)-, or (v) a group of formula —C(═O)NHR6 wherein R6 is primary, secondary, tertiary or cyclic amino, or hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1-C6alkyl)-, or heteroaryKC1-C6alkoxy)-.
    • 式(I)化合物是HSP90抑制剂,可用于治疗例如癌症:其中R1是 - (Alk1)对(Z)r(Alk2)-Q其中Alk1和AIk2是任选取代的二价C1C3亚烷基 或C 2 -C 3亚烯基,p,r和s独立地为0或1,Z为-O - , - S-, -​​ (CO) - , - (CS) - , - SO 2 - O-,-C(-O)NRA,-C(-S)NRA,-SO2NRA-NRAC(-O) - ,-NRASO2-或-NRA-,其中RA是氢或C1-C6烷基,Q是 氢或任选取代的碳环或杂环基; R2是任选取代的芳基或杂芳基; R 3是氢,任选的取代基,或任选取代的(C 1 -C 6)烷基,芳基或杂芳基; 和(ⅲ)任选取代的C 1 -C 6烷基,芳基,杂芳基,芳基(C 1 -C 6烷基) - 或杂芳基(C 1 -C 6烷基) C 1 -C 6烷基) - 基,或(iv)式-C( - O)R 5基团,其中R 5是羟基,任选取代的C 1 -C 6烷基,C 1 -C 6烷氧基,芳基,芳氧基,杂芳基,杂芳氧基, ) - ,芳基(C 1 -C 6烷氧基) - ,杂芳基(C 1 -C 6烷基) - 或杂芳基(C 1 -C 6烷氧基) - 或(v)式-C(-O)NHR 6基团, C 1 -C 6烷氧基,芳氧基,杂芳基,杂芳氧基,芳基(C 1 -C 6烷基) - ,芳基(C 1 -C 6烷氧基) - ,杂芳基(C 1 -C 6烷基) - 或杂基KCl-C6烷氧基) - 。